Candidate Nomination in Record Time
- Fast follow on: competitors in phase I/II
- Therapeutic indication: Identify new indication(s) other than competitors and/or differentiation over current indication in clinic
- Identify novel hit for analoging in absence of HTS screen
- Deliver CCN in two years
Eurofins Advinus Approach
- Novel and diverse six chemotypes designed to carry out parallel SAR to identify HITS in first three months
- Identified four HITS and prioritized two series to provide two LEADS within 6 months
- Developed novel in-vivo PD Assay
- Nominated Optimized Lead for Candidate Selection within 10 months
- Progress was halted due to phototoxicity and human hepatocyte instability
- Second lead series showed CYP TDI liability
- SAR knowledge from earlier two series helped to design a new chemotype (Third) to overcome above hurdles in time
- Identified new indication by exploring efficacy in various disease models and data mining with clients help
- Identified clinical candidate with excellent efficacy and good therapeutic window and potential back-up compound is being profiled
Achievements
- Filed three chemical composition of matter patents
- This programs achieved clinical candidate nomination milestone from collaborator
Current Status
- Nominated clinical candidate is being profiled for new indication and IND enabling studies ongoing.